Sign in →

Test ID: CHRST Chromosome Analysis, Solid Tumors

Useful For

Assisting in the classification of malignant tumors associated with chromosomal abnormalities

Reflex Tests

Test ID Reporting Name Available Separately Always Performed
_ML20 Metaphases, 1-19 No, (Bill Only) No
_M25 Metaphases, 20-25 No, (Bill Only) No
_MG25 Metaphases, >25 No, (Bill Only) No
_STAC Ag-Nor/CBL Stain No, (Bill Only) No

Testing Algorithm

This test includes a charge for cell culture of fresh specimens and professional interpretation of results. Analysis charges will be incurred for total work performed, and generally include 2 banded karyograms and the analysis of 20 metaphase cells. If no metaphase cells are available for analysis, no analysis charges will be incurred. If additional analysis work is required, additional charges may be incurred.


Method Name

Cell Culture followed by Chromosome Analysis

Reporting Name

Chromosomes, Solid Tumor

Specimen Type


Specimen Required

Provide a reason for referral with each specimen. The laboratory will not reject testing if this information is not provided, but appropriate testing and interpretation may be compromised or delayed. Include pathology reports, if available.


Container/Tube: Sterile container with sterile Hank's balanced salt solution (T132), Ringer's solution, or normal saline

Specimen Volume: 0.5-3 cm(3) or larger

Additional Information: Advise Express Mail or equivalent if not on courier service.

Specimen Minimum Volume

0.5 cm(3)

Specimen Stability Information

Specimen Type Temperature Time
Tissue Refrigerated (preferred)

Clinical Information

Most malignant neoplasms are associated with clonal genetic abnormalities and the observation of an abnormal cytogenetic clone is consistent with a neoplasm. In many instances, these abnormalities can be demonstrated by cytogenetic analysis. Some physicians now consider cytogenetic analysis a useful laboratory test to determine the neoplastic potential of solid tumors.


For some tumors, cytogenetic analysis can help classify solid tumors. For example, an X;18 translocation has been specifically associated with synovial sarcoma, many alveolar rhabdomyosarcomas have an associated 2;13 translocation, and nearly every myxoid liposarcoma has a 12;16 translocation. A complete summary of the correlation between tumor histology and specific chromosome anomalies is too extensive to summarize here. The reader is referred to the Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer. 2014 Available at URL:

Reference Values

An interpretive report will be provided.


The observation of a chromosomally abnormal clone is evidence of a clonal neoplastic process.


Certain chromosome abnormalities may also be specifically associated with certain morphologic classifications. In many tumors, the cytogenetic interpretation may be complicated by the observation of numerous complex chromosome anomalies. Nevertheless, the presence of certain chromosome abnormalities within a complex karyotype may still aid in classifying the tumor. However, a normal karyotype does not eliminate the possibility of a neoplastic process. Additionally, FISH testing or other strategies may be more appropriate for certain tumor types.


On rare occasions, the presence of an abnormality may be associated with a congenital abnormality that is not related to a malignant neoplastic process. Follow-up with a medical genetics consultation is recommended.

Clinical Reference

1. Sandberg AA, Turc-Carel C, Gemmell RM: Chromosomes in solid tumors and beyond. Cancer Res 1988;48:1049-1059

2. Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer. Edited by F Mitelman, B Johansson, F Mertens. 2014, Available from URL:

Day(s) and Time(s) Performed

Samples processed Monday through Sunday. Results reported Monday through Friday, 8 a.m-5 p.m. CST.

Analytic Time

15 to 50 days, depending on culture growth

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information

88239, 88291- Tissue culture for tumor, Interpretation and report

88264 w/modifier 52-Chromosome analysis <20 cells (if appropriate)

88264-Chromosome analysis with 20 to 25 cells (if appropriate)

88264, 88285 - Chromosome analysis with >25 cells (if appropriate)

88283-Additional specialized banding technique (if appropriate) 


LOINC Code Information

Test ID Test Order Name Order LOINC Value
CHRST Chromosomes, Solid Tumor In Process


Result ID Test Result Name Result LOINC Value
52350 Result Summary 50397-9
52352 Interpretation 69965-2
52351 Result 82939-0
CG773 Reason for Referral 42349-1
52353 Specimen 31208-2
52354 Source 31208-2
52356 Method 49549-9
52355 Banding Method 62359-5
54628 Additional Information 48767-8
52357 Released By 18771-6
Mayo Clinic Laboratories | Oncology Catalog Additional Information:

MML-Bone-and-Soft-Tissue-Cancer, MML-Breast-Cancer, MML-Endocrine-Cancer, MML-Gastrointestinal-Cancer, MML-Gynegological-Cancer, MML-Head-Neck-Cancer, MML-Neuro-Oncology-oms, MML-Pulmonary-Cancer, MML-Skin-Cancer, mml-Genitourinary-Cancer